Cardiac neoplasm

Verify with FDA CVM →

VeDDRA Code: 2309

80 adverse event reports referencing this reaction

80
Total Reports
54
Deaths
6750.0%
Death Rate

Species Most Affected

Dog 77
Cat 3

Breeds Most Affected

Retriever - Labrador 8
Crossbred Canine/dog 7
Retriever - Golden 5
Bulldog 5
Dog (unknown) 5
Boxer (German Boxer) 4
Shepherd Dog - Australian 3
Pug 3
Terrier - Boston 3
Shih Tzu 2

Associated Drugs

Milbemycin Oxime + Spinosad 18
Oclacitinib Maleate 15
Fluralaner Chew Tablets 6
Spinosad 5
Maropitant Citrate 5
Imidacloprid + Moxidectin 4
Pimobendan 4
Ivermectin + Pyrantel As Pamoate Salt 4
Cyclosporine 3
Carprofen 3
Trilostane 3
Deracoxib 3
Diphenhydramine Hcl 3
Polysulfated Glycosaminoglycan 2
Prednisolone; Trimeprazine Tartrate 2
Thyroxine 2
Moxidectin 2
Afoxolaner 2
Metronidazole 2
Cefovecin 2

Data Summary

Metric Value
Total reports referencing reaction 80
Reports with fatal outcome 54
Case-fatality rate (reported events) 6750.0%
Species observed 2
Breeds observed 20
Drugs associated with reaction 20

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER); reaction term coded under VeDDRA 2309.

Cardiac neoplasm Reaction Insights

The FDA Center for Veterinary Medicine database currently lists 80 adverse event reports that reference Cardiac neoplasm as a reaction term, including 54 reports with a death outcome — a 6750.0% case-fatality figure calculated across only those events where this reaction was coded. The reaction is indexed in the openFDA system under VeDDRA code 2309, the standardized veterinary dictionary used to normalize clinical signs across submitters. Because reports are voluntary and often describe multiple concurrent signs per animal, the volume here reflects reporting intensity rather than true incidence in the broader pet population.

Cardiac neoplasm appears most frequently in reports for Dog (77 reports), Cat (3 reports) — with Dog dominating at 77 entries. Within those species, the breeds most often named alongside this reaction are Retriever - Labrador (8), Crossbred Canine/dog (7), Retriever - Golden (5). These distributions are influenced both by underlying breed popularity and by how veterinarians and owners code a given clinical sign, so they should be interpreted as a reporting fingerprint rather than a pure susceptibility ranking.

The drugs most commonly co-reported with Cardiac neoplasm are Milbemycin Oxime + Spinosad (18 reports), Oclacitinib Maleate (15 reports), Fluralaner Chew Tablets (6 reports), Spinosad (5 reports), with Milbemycin Oxime + Spinosad appearing alongside this reaction in 18 submissions. Co-reporting does not establish that any specific product caused the reaction — FDA CVM data captures temporal association only. The value of these aggregates is in flagging which therapeutic classes appear repeatedly alongside a given clinical sign, so owners and veterinarians can ask targeted questions about medications currently in use.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial